This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The concentration of netarsudil in the vitreous to assess its pharmacokinetic properties.
Timeframe: Through study completion, an average of 1 year
Serious adverse events
Timeframe: Day 1, 7, 28, 84, and 168 after surgery